Jun Inamo, Joshua Keegan, Alec Griffith, Tusharkanti Ghosh, Alice Horisberger, Kaitlyn Howard, John F Pulford, Ekaterina Murzin, Brandon Hancock, Salina T Dominguez, Miranda G Gurra, Siddarth Gurajala, Anna Helena Jonsson, Jennifer A Seifert, Marie L Feser, Jill M Norris, Ye Cao, William Apruzzese, S Louis Bridges, Vivian P Bykerk, Susan Goodman, Laura T Donlin, Gary S Firestein, Joan M Bathon, Laura B Hughes, Andrew Filer, Costantino Pitzalis, Jennifer H Anolik, Larry Moreland, Nir Hacohen, Joel M Guthridge, Judith A James, Carla M Cuda, Harris Perlman, Michael B Brenner, Soumya Raychaudhuri, Jeffrey A Sparks, V Michael Holers, Kevin D Deane, James Lederer, Deepak A Rao, Fan Zhang
{"title":"深度免疫分型揭示类风湿关节炎高危个体循环活化淋巴细胞。","authors":"Jun Inamo, Joshua Keegan, Alec Griffith, Tusharkanti Ghosh, Alice Horisberger, Kaitlyn Howard, John F Pulford, Ekaterina Murzin, Brandon Hancock, Salina T Dominguez, Miranda G Gurra, Siddarth Gurajala, Anna Helena Jonsson, Jennifer A Seifert, Marie L Feser, Jill M Norris, Ye Cao, William Apruzzese, S Louis Bridges, Vivian P Bykerk, Susan Goodman, Laura T Donlin, Gary S Firestein, Joan M Bathon, Laura B Hughes, Andrew Filer, Costantino Pitzalis, Jennifer H Anolik, Larry Moreland, Nir Hacohen, Joel M Guthridge, Judith A James, Carla M Cuda, Harris Perlman, Michael B Brenner, Soumya Raychaudhuri, Jeffrey A Sparks, V Michael Holers, Kevin D Deane, James Lederer, Deepak A Rao, Fan Zhang","doi":"10.1172/JCI185217","DOIUrl":null,"url":null,"abstract":"<p><p>Rheumatoid arthritis (RA) is a systemic autoimmune disease currently with no universally highly effective prevention strategies. Identifying pathogenic immune phenotypes in at-risk populations prior to clinical onset is crucial to establishing effective prevention strategies. Here, we applied multimodal single-cell technologies (mass cytometry and CITE-Seq) to characterize the immunophenotypes in blood from at-risk individuals (ARIs) identified through the presence of serum antibodies against citrullinated protein antigens (ACPAs) and/or first-degree relative (FDR) status, as compared with patients with established RA and people in a healthy control group. We identified significant cell expansions in ARIs compared with controls, including CCR2+CD4+ T cells, T peripheral helper (Tph) cells, type 1 T helper cells, and CXCR5+CD8+ T cells. We also found that CD15+ classical monocytes were specifically expanded in ACPA-negative FDRs, and an activated PAX5lo naive B cell population was expanded in ACPA-positive FDRs. Further, we uncovered the molecular phenotype of the CCR2+CD4+ T cells, expressing high levels of Th17- and Th22-related signature transcripts including CCR6, IL23R, KLRB1, CD96, and IL22. Our integrated study provides a promising approach to identify targets to improve prevention strategy development for RA.</p>","PeriodicalId":15469,"journal":{"name":"Journal of Clinical Investigation","volume":"135 6","pages":""},"PeriodicalIF":13.3000,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11910230/pdf/","citationCount":"0","resultStr":"{\"title\":\"Deep immunophenotyping reveals circulating activated lymphocytes in individuals at risk for rheumatoid arthritis.\",\"authors\":\"Jun Inamo, Joshua Keegan, Alec Griffith, Tusharkanti Ghosh, Alice Horisberger, Kaitlyn Howard, John F Pulford, Ekaterina Murzin, Brandon Hancock, Salina T Dominguez, Miranda G Gurra, Siddarth Gurajala, Anna Helena Jonsson, Jennifer A Seifert, Marie L Feser, Jill M Norris, Ye Cao, William Apruzzese, S Louis Bridges, Vivian P Bykerk, Susan Goodman, Laura T Donlin, Gary S Firestein, Joan M Bathon, Laura B Hughes, Andrew Filer, Costantino Pitzalis, Jennifer H Anolik, Larry Moreland, Nir Hacohen, Joel M Guthridge, Judith A James, Carla M Cuda, Harris Perlman, Michael B Brenner, Soumya Raychaudhuri, Jeffrey A Sparks, V Michael Holers, Kevin D Deane, James Lederer, Deepak A Rao, Fan Zhang\",\"doi\":\"10.1172/JCI185217\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Rheumatoid arthritis (RA) is a systemic autoimmune disease currently with no universally highly effective prevention strategies. Identifying pathogenic immune phenotypes in at-risk populations prior to clinical onset is crucial to establishing effective prevention strategies. Here, we applied multimodal single-cell technologies (mass cytometry and CITE-Seq) to characterize the immunophenotypes in blood from at-risk individuals (ARIs) identified through the presence of serum antibodies against citrullinated protein antigens (ACPAs) and/or first-degree relative (FDR) status, as compared with patients with established RA and people in a healthy control group. We identified significant cell expansions in ARIs compared with controls, including CCR2+CD4+ T cells, T peripheral helper (Tph) cells, type 1 T helper cells, and CXCR5+CD8+ T cells. We also found that CD15+ classical monocytes were specifically expanded in ACPA-negative FDRs, and an activated PAX5lo naive B cell population was expanded in ACPA-positive FDRs. Further, we uncovered the molecular phenotype of the CCR2+CD4+ T cells, expressing high levels of Th17- and Th22-related signature transcripts including CCR6, IL23R, KLRB1, CD96, and IL22. Our integrated study provides a promising approach to identify targets to improve prevention strategy development for RA.</p>\",\"PeriodicalId\":15469,\"journal\":{\"name\":\"Journal of Clinical Investigation\",\"volume\":\"135 6\",\"pages\":\"\"},\"PeriodicalIF\":13.3000,\"publicationDate\":\"2025-03-17\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11910230/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Clinical Investigation\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1172/JCI185217\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"MEDICINE, RESEARCH & EXPERIMENTAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Clinical Investigation","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1172/JCI185217","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
Deep immunophenotyping reveals circulating activated lymphocytes in individuals at risk for rheumatoid arthritis.
Rheumatoid arthritis (RA) is a systemic autoimmune disease currently with no universally highly effective prevention strategies. Identifying pathogenic immune phenotypes in at-risk populations prior to clinical onset is crucial to establishing effective prevention strategies. Here, we applied multimodal single-cell technologies (mass cytometry and CITE-Seq) to characterize the immunophenotypes in blood from at-risk individuals (ARIs) identified through the presence of serum antibodies against citrullinated protein antigens (ACPAs) and/or first-degree relative (FDR) status, as compared with patients with established RA and people in a healthy control group. We identified significant cell expansions in ARIs compared with controls, including CCR2+CD4+ T cells, T peripheral helper (Tph) cells, type 1 T helper cells, and CXCR5+CD8+ T cells. We also found that CD15+ classical monocytes were specifically expanded in ACPA-negative FDRs, and an activated PAX5lo naive B cell population was expanded in ACPA-positive FDRs. Further, we uncovered the molecular phenotype of the CCR2+CD4+ T cells, expressing high levels of Th17- and Th22-related signature transcripts including CCR6, IL23R, KLRB1, CD96, and IL22. Our integrated study provides a promising approach to identify targets to improve prevention strategy development for RA.
期刊介绍:
The Journal of Clinical Investigation, established in 1924 by the ASCI, is a prestigious publication that focuses on breakthroughs in basic and clinical biomedical science, with the goal of advancing the field of medicine. With an impressive Impact Factor of 15.9 in 2022, it is recognized as one of the leading journals in the "Medicine, Research & Experimental" category of the Web of Science.
The journal attracts a diverse readership from various medical disciplines and sectors. It publishes a wide range of research articles encompassing all biomedical specialties, including Autoimmunity, Gastroenterology, Immunology, Metabolism, Nephrology, Neuroscience, Oncology, Pulmonology, Vascular Biology, and many others.
The Editorial Board consists of esteemed academic editors who possess extensive expertise in their respective fields. They are actively involved in research, ensuring the journal's high standards of publication and scientific rigor.